Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced positive results from the Phase 3 tranquility trial, which achieved its primary endpoint of being statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test (p=0.0001) and ≥10 mm Schirmer test responder proportions (p<0.0001)...
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), a clinical-stage pharmaceutical company, developing immunotherapy to prevent breast cancer recurrence in patients who previously underwent surgery, announced the removal of the clinical hold on the Phase III Flamingo-01 clinical trial by the U.S Food and Drug Administration (FDA). The FDA...
Positive Results from Phase 3 trial of Sabizabulin Veru, Inc. (NASDAQ: VERU) announced the publication of results from a Phase 3 study evaluating the safety and efficacy of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome...
Iveric Bio, Inc. ( NASDAQ: ISEE) is a clinical-stage biopharmaceutical company developing transformative therapies for retinal diseases with significant unmet needs. The Company is developing a diverse portfolio of therapeutic candidates at various stages of development. The Company’s lead product candidate is Zimura (avacincaptad pegol),...
Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN). The MISSION Phase 2 trial is an open-label study with...
Emergent BioSolutions, Inc. (NYSE: EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the acceptance of a Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) by the U.S. Food and Drug Administration (FDA). The...
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. The...
Geron Corporation, Inc. (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor, imetelstat, intended to treat hematologic malignancies. The Company’s lead candidate Imetelstat is a novel first-in-class telomerase inhibitor currently undergoing a Phase 3 trial, IMerge, which is a double-blind, randomized,...
Twist Biosciences, Inc. (NASDAQ: TWST) manufactures and sells synthetic DNA-based products by leveraging the Company’s DNA synthesis platform that helps write DNA on a silicon chip. The Company offers products such as synthetic genes, sample preparation tools, antibody libraries for drug discovery and development, and...
Harmony Biosciences, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical Company developing novel therapeutics for rare and orphan diseases, focusing on central nervous system disorders. Pitolisant, its lead product candidate, is a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist that can help treat excessive daytime sleepiness...
